| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Metalidis C et al. | Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. | 2011 | Transplantation | pmid:21544031 |
| Shihab FS et al. | Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. | 2008 | Transplantation | pmid:18475181 |
| Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
| Fischer L et al. | Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. | 2015 | Transplantation | pmid:26151607 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Shirakata Y et al. | Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. | 1995 | Transplantation | pmid:8545894 |
| First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
| Leroy-Matheron C et al. | Inhibitor against coagulation factor V after liver transplantation. | 1999 | Transplantation | pmid:10532550 |
| Takaya S et al. | The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. | 1992 | Transplantation | pmid:1371195 |
| Abbott KC et al. | New-onset gout after kidney transplantation: incidence, risk factors and implications. | 2005 | Transplantation | pmid:16340779 |
| Bayer ND et al. | Association of metabolic syndrome with development of new-onset diabetes after transplantation. | 2010 | Transplantation | pmid:20724958 |
| Krentz AJ et al. | Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. | 1994 | Transplantation | pmid:7516590 |
| Kiuchi T et al. | A hepatic graft tuberculosis transmitted from a living-related donor. | 1997 | Transplantation | pmid:9089234 |
| Heilman RL et al. | Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. | 2012 | Transplantation | pmid:22067270 |
| Mourad G et al. | Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial. | 2017 | Transplantation | pmid:27547871 |
| Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
| David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
| Newell KA et al. | Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. | 1996 | Transplantation | pmid:8779685 |
| Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
| Bellon H et al. | The Effect of Immunosuppression on Airway Integrity. | 2017 | Transplantation | pmid:28471870 |
| Lufft V et al. | Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. | 1996 | Transplantation | pmid:8779695 |
| Barten MJ et al. | Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. | 2004 | Transplantation | pmid:15114077 |
| Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
| Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
| Yamazaki S et al. | Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. | 2008 | Transplantation | pmid:18852671 |
| Kiuchi T | CNIs: immediate benefits but storing problems for the future? | 2008 | Transplantation | pmid:18946338 |
| Stevens RB et al. | A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. | 2015 | Transplantation | pmid:25083614 |
| Ravaioli M et al. | Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. | 2015 | Transplantation | pmid:25757214 |
| Ciancio G et al. | The use of Campath-1H as induction therapy in renal transplantation: preliminary results. | 2004 | Transplantation | pmid:15316372 |
| Florescu DF et al. | Adenovirus infections in pediatric small bowel transplant recipients. | 2010 | Transplantation | pmid:20467354 |
| Vafadari R et al. | Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry. | 2012 | Transplantation | pmid:22643331 |
| Morales JM et al. | Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. | 2008 | Transplantation | pmid:18724234 |
| Opelz G and Döhler B | Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. | 2008 | Transplantation | pmid:18698238 |
| Gallon LG et al. | Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. | 2007 | Transplantation | pmid:17519781 |
| Apanay DC et al. | Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. | 1994 | Transplantation | pmid:7524202 |
| Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
| Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
| Roberti I et al. | Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. | 1992 | Transplantation | pmid:1384182 |
| Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
| Gruessner RW et al. | Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. | 1998 | Transplantation | pmid:9701258 |
| Pascual J et al. | Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. | 2010 | Transplantation | pmid:20335831 |
| Raggi MC et al. | Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. | 2010 | Transplantation | pmid:21076373 |
| Sahara H et al. | Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. | 2010 | Transplantation | pmid:21076382 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Ueki S et al. | Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. | 2006 | Transplantation | pmid:17198266 |
| Ellis D et al. | Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. | 1991 | Transplantation | pmid:1714643 |
| Murase N et al. | Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. | 1993 | Transplantation | pmid:7678353 |
| Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
| Wong W et al. | 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? | 2005 | Transplantation | pmid:16082321 |
| Krämer BK et al. | Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. | 2012 | Transplantation | pmid:22858806 |